JP2020534246A5 - - Google Patents

Download PDF

Info

Publication number
JP2020534246A5
JP2020534246A5 JP2019571517A JP2019571517A JP2020534246A5 JP 2020534246 A5 JP2020534246 A5 JP 2020534246A5 JP 2019571517 A JP2019571517 A JP 2019571517A JP 2019571517 A JP2019571517 A JP 2019571517A JP 2020534246 A5 JP2020534246 A5 JP 2020534246A5
Authority
JP
Japan
Prior art keywords
patent document
domperidone
dopamine
receptors
increase
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019571517A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020534246A (ja
JP7602324B2 (ja
Filing date
Publication date
Priority claimed from US15/639,431 external-priority patent/US10266516B2/en
Application filed filed Critical
Publication of JP2020534246A publication Critical patent/JP2020534246A/ja
Publication of JP2020534246A5 publication Critical patent/JP2020534246A5/ja
Priority to JP2022205876A priority Critical patent/JP2023052045A/ja
Application granted granted Critical
Publication of JP7602324B2 publication Critical patent/JP7602324B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019571517A 2016-02-04 2018-06-28 重水素化ドンペリドン組成物、方法、及び調製 Active JP7602324B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2022205876A JP2023052045A (ja) 2016-02-04 2022-12-22 重水素化ドンペリドン組成物、方法、及び調製

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201662291198P 2016-02-04 2016-02-04
US15/639,431 2017-06-30
US15/639,431 US10266516B2 (en) 2016-02-04 2017-06-30 Deuterated domperidone compositions, methods, and preparation
PCT/US2018/039928 WO2019006078A1 (en) 2016-02-04 2018-06-28 DETERERATED DOMPERIDONE COMPOSITIONS, METHODS AND PREPARATION

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022205876A Division JP2023052045A (ja) 2016-02-04 2022-12-22 重水素化ドンペリドン組成物、方法、及び調製

Publications (3)

Publication Number Publication Date
JP2020534246A JP2020534246A (ja) 2020-11-26
JP2020534246A5 true JP2020534246A5 (enExample) 2021-08-19
JP7602324B2 JP7602324B2 (ja) 2024-12-18

Family

ID=59501077

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2018535888A Active JP7296185B2 (ja) 2016-02-04 2017-02-03 重水素化ドンペリドン組成物及び疾患の治療方法
JP2019571517A Active JP7602324B2 (ja) 2016-02-04 2018-06-28 重水素化ドンペリドン組成物、方法、及び調製
JP2022205876A Pending JP2023052045A (ja) 2016-02-04 2022-12-22 重水素化ドンペリドン組成物、方法、及び調製

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2018535888A Active JP7296185B2 (ja) 2016-02-04 2017-02-03 重水素化ドンペリドン組成物及び疾患の治療方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2022205876A Pending JP2023052045A (ja) 2016-02-04 2022-12-22 重水素化ドンペリドン組成物、方法、及び調製

Country Status (11)

Country Link
US (2) US10266516B2 (enExample)
EP (2) EP3411031B1 (enExample)
JP (3) JP7296185B2 (enExample)
KR (2) KR102851614B1 (enExample)
CN (4) CN113995755A (enExample)
AU (2) AU2017213852B2 (enExample)
BR (2) BR112018016032B1 (enExample)
CA (2) CA3013123A1 (enExample)
DK (2) DK3411031T3 (enExample)
EA (2) EA035515B1 (enExample)
WO (2) WO2017136617A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3288556A4 (en) 2015-04-29 2018-09-19 Dexcel Pharma Technologies Ltd. Orally disintegrating compositions
CN113995755A (zh) * 2016-02-04 2022-02-01 辛多美制药有限公司 氘代多潘立酮组合物和用于治疗病症的方法
US10076494B2 (en) 2016-06-16 2018-09-18 Dexcel Pharma Technologies Ltd. Stable orally disintegrating pharmaceutical compositions
US12478612B2 (en) 2017-06-30 2025-11-25 Cindome Pharma, Inc. Deuterated domperidone compositions, methods, and preparation
KR20240125702A (ko) 2017-06-30 2024-08-19 신돔 파마, 인크. 중수소화 돔페리돈 조성물, 방법, 및 제조
AU2019290231A1 (en) * 2018-06-21 2020-12-17 Dermavant Sciences GmbH Topical formulations of DGAT1 inhibitors and their methods of use
CA3117682A1 (en) * 2018-10-25 2020-04-30 Cindome Pharma, Inc. Formulations containing deuterated domperidone
KR20210082480A (ko) * 2018-10-25 2021-07-05 신돔 파마, 인크. 돔페리돈을 함유하는 제제
WO2022212246A1 (en) * 2021-03-29 2022-10-06 The Government Of The United States Of America, As Represented By The Secretary Of The Navy Multi-enzyme nanoparticle-assisted stable isotope incorporation into small molecules by channeling
IL316105A (en) * 2022-04-20 2024-12-01 Cindome Pharma Inc Deuterium-enhanced domperidone for the treatment of gastroparesis
CN120813355A (zh) * 2023-03-23 2025-10-17 辛多美制药有限公司 用于治疗糖尿病性胃轻瘫的方法

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4066772A (en) * 1975-07-21 1978-01-03 Janssen Pharmaceutica N.V. 1,3-Dihydro-1-[3-(1-piperidinyl)propyl]-2H-benzimidazol-2-ones and related compounds
NZ181256A (en) * 1975-07-21 1978-04-28 Janssen Pharmaceutica Nv 1-(w-benzazol-11-ylalkyl)-piperidine derivatives and pharmaceutical compositions containing certain of these derivatives
TW466119B (en) * 1994-02-28 2001-12-01 Janssen Pharmaceutica Nv Film coated tablet of paracetamol and domperidone
FR2725986B1 (fr) * 1994-10-21 1996-11-29 Adir Nouveaux derives de piperidine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
US5773031A (en) 1996-02-27 1998-06-30 L. Perrigo Company Acetaminophen sustained-release formulation
US20160206639A9 (en) 2001-10-12 2016-07-21 Monosol Rx, Llc Films and Drug Delivery Systems Made Therefrom
US20140163060A1 (en) 2001-10-12 2014-06-12 Monosol Rx, Llc Films and Drug Delivery Systems Made Therefrom
US20140271788A1 (en) 2013-03-15 2014-09-18 Monosol Rx, Llc Sublingual and buccal film compositions
US20140070440A1 (en) 2001-10-12 2014-03-13 Monosol Rx, Llc Films and Drug Delivery Systems Made Therefrom
US20130220526A1 (en) 2001-10-12 2013-08-29 Monosol Rx, Llc Films and Drug Delivery Systems Made Therefrom
ITMI20020514A1 (it) 2002-03-12 2003-09-12 Jagotec Ag Sistema terapeutico per il rilascio controllato di uno o piu' principi attivi
US9101540B2 (en) 2002-04-12 2015-08-11 Alkermes Pharma Ireland Limited Nanoparticulate megestrol formulations
EP1545475B1 (en) 2002-10-01 2014-07-16 Banner Pharmacaps, Inc. Enteric composition for the manufacture of soft capsule wall
US7387793B2 (en) 2003-11-14 2008-06-17 Eurand, Inc. Modified release dosage forms of skeletal muscle relaxants
NZ555719A (en) 2004-12-31 2010-11-26 Iceutica Pty Ltd Nanoparticle composition and methods for synthesis thereof
ITMI20050477A1 (it) 2005-03-23 2006-09-24 Bouty S P A Cerotto transdermico
CN100386323C (zh) * 2006-02-27 2008-05-07 南京长澳医药科技有限公司 马来酸多潘立酮的合成方法
US8846100B2 (en) 2006-05-12 2014-09-30 Shire Llc Controlled dose drug delivery system
NZ705763A (en) 2006-06-30 2016-10-28 Iceutica Pty Ltd Methods for the preparation of biologically active compounds in nanoparticulate form
EP2142176A1 (en) * 2007-04-26 2010-01-13 Craig A. Aronchick Compositions and methods for transmucosal delivery of domperidone
ES2438267T3 (es) 2007-08-15 2014-01-16 Mcneil-Ppc, Inc. Régimen de dosificación de ibuprofeno de liberación inmediata y de liberación sostenida
US20090131485A1 (en) 2007-09-10 2009-05-21 Concert Pharmaceuticals, Inc. Deuterated pirfenidone
US20090076010A1 (en) 2007-09-13 2009-03-19 Protia, Llc Deuterium-enriched lamotrigine
US20110160253A1 (en) 2008-05-28 2011-06-30 Harbeson Scott L Deuterated tizanidine
WO2010054003A2 (en) * 2008-11-06 2010-05-14 Auspex Pharmaceutical, Inc. Methylindazole modulators of 5-ht3 receptors
WO2010054158A2 (en) * 2008-11-07 2010-05-14 Auspex Pharmaceuticals, Inc. Steroid modulators of glucocorticoid receptor
AP2015008955A0 (en) 2009-04-24 2015-12-31 Icuetica Pty Ltd A novel formulation of indomethacin
NZ595985A (en) 2009-04-24 2014-07-25 Iceutica Pty Ltd A novel formulation of naproxen
NZ595903A (en) 2009-04-24 2014-03-28 Iceutica Pty Ltd A novel formulation of metaxalone
US20120160944A1 (en) 2009-04-24 2012-06-28 Aaron Dodd Method for the production of commercial nanoparticle and micro particle powders
MX337619B (es) 2009-04-24 2016-03-10 Iceutica Pty Ltd Una formulacion novedosa de diclofenaco.
US20140017299A1 (en) 2011-08-18 2014-01-16 Monosol Rx, Llc Steroid hormone delivery systems and methods of preparing the same
CN107441069A (zh) 2012-02-28 2017-12-08 日绊株式会社 贴附剂
EA201492287A1 (ru) 2012-06-15 2015-07-30 Консерт Фармасьютикалс, Инк. Дейтерированные производные руксолитиниба
CA2877122C (en) * 2012-06-19 2020-04-28 Intercept Pharmaceuticals, Inc. Preparation, uses and solid forms of obeticholic acid
US20140019395A1 (en) 2012-07-12 2014-01-16 Craig Charles Bauer Method and application of Fear, Love and Methodology as protocols within and of a programming group, as a means of creating an artificial individual, software system or other independent entity capable of independent self directive creation of choice and/or self directive creation of purpose within a virtual and/or any environment
AU2014236597A1 (en) 2013-03-14 2015-09-24 Deuterx, Llc 3-(substituted-4-oxo-quinazolin-3(4H)-yl)-3-deutero-piperidine-2,6-dione derivatives
US20140272220A1 (en) 2013-03-15 2014-09-18 Monosol Rx, Llc Reduction in stress cracking of films
US20140271787A1 (en) 2013-03-15 2014-09-18 Monosol Rx, Llc Continuous single layer film structure including discrete domains
KR20160023641A (ko) 2013-03-15 2016-03-03 아이슈티카 인코포레이티드 아비라테론 아세테이트 제제
CN113995755A (zh) 2016-02-04 2022-02-01 辛多美制药有限公司 氘代多潘立酮组合物和用于治疗病症的方法

Similar Documents

Publication Publication Date Title
JP2020534246A5 (enExample)
JP2021505241A5 (enExample)
JP2019514354A5 (enExample)
JP2019502892A5 (enExample)
JP2019504068A5 (enExample)
WO2002076925A3 (en) Non-imidazole aryl alkylamines compounds as histamine h3 receptor antagonists, preparation and therapeutic uses
JP2006526031A5 (enExample)
JP2019536800A5 (enExample)
EA200600049A1 (ru) Способы получения 3 - бензазепинов
JP2013540292A5 (enExample)
NO20050012L (no) N-aryldiazaspiracykliske forbindelser og fremgangsmater for fremstilling og anvendelse derav
EA200701299A1 (ru) Производные стильбена и их применение для связывания и визуализации амилоидных бляшек
ATE438632T1 (de) Aryl-4-ethinylisoxazolderivate
JP2018525453A5 (enExample)
JP2020512939A5 (enExample)
NO20092092L (no) Arylsulfamidderivater og fremgangsmater for anvendelse derav
CY1112392T1 (el) Κρυσταλλικη βαση εσκιταλοπραμης και δισκια διασπειρομενα στο στομα που αποτελουνται απο βαση εσκιταλοπραμης
RU2017102513A (ru) Соль гетероциклического соединения, замещенного галогеном
EA200600071A1 (ru) Производные n-фенилпиперазина и способы профилактики или лечения заболеваний, связанных с 5ht-рецептором
RU2427573C2 (ru) Новые производные бензимидазола в качестве ингибиторов ваниллоидного рецептора 1 (vr1)
JP2020500643A5 (enExample)
BRPI0612189A2 (pt) composto, composiÇço farmacÊutica, mÉtodo para ligar receptores opiàides
JP2014508098A5 (enExample)
JP2021502362A5 (enExample)
JP2009523456A5 (enExample)